精神分裂症合并代谢综合征或代谢异常患者换药策略综述
A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities.
作者信息
Liao Xuemei, Ye Hui, Si Tianmei
机构信息
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, People's Republic of China.
Medical Department, Sanofi, Shanghai, People's Republic of China.
出版信息
Neuropsychiatr Dis Treat. 2021 Feb 11;17:453-469. doi: 10.2147/NDT.S294521. eCollection 2021.
Abstract
Metabolic syndrome (MetS) in patients with schizophrenia occurs 2-3 times more frequently than in the general population. Antipsychotic medication is a primary risk factor for patients with MetS. In particular, the widely used second-generation antipsychotics can affect glucose and lipid metabolism and can induce insulin resistance and other metabolic abnormalities through various receptors. Notably, the metabolic risks of various antipsychotics may differ because of their different pharmacological affinity to MetS-related receptors. Several previous studies have shown that switching from high to low metabolic risk antipsychotics may improve patients' metabolic parameters. The current review aims to discuss the strategies for switching antipsychotic medications and the impact on metabolic abnormalities in patients with schizophrenia.
摘要
精神分裂症患者的代谢综合征（MetS）发生率比普通人群高2至3倍。抗精神病药物是患代谢综合征患者的主要风险因素。特别是，广泛使用的第二代抗精神病药物会影响葡萄糖和脂质代谢，并可通过各种受体诱导胰岛素抵抗和其他代谢异常。值得注意的是，由于各种抗精神病药物对与代谢综合征相关受体的药理亲和力不同，其代谢风险可能存在差异。先前的几项研究表明，从高代谢风险抗精神病药物转换为低代谢风险抗精神病药物可能会改善患者的代谢参数。本综述旨在讨论抗精神病药物的转换策略以及对精神分裂症患者代谢异常的影响。
相似文献
1
A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities.精神分裂症合并代谢综合征或代谢异常患者换药策略综述
Neuropsychiatr Dis Treat. 2021 Feb 11;17:453-469. doi: 10.2147/NDT.S294521. eCollection 2021.
2
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.典型和非典型抗精神病药物对首发精神分裂症患者代谢综合征的长期发病率有不同影响：一项回顾性病历审查。
Schizophr Res. 2008 Apr;101(1-3):295-303. doi: 10.1016/j.schres.2008.01.028. Epub 2008 Mar 4.
3
The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.齐拉西酮对精神分裂症患者代谢综合征危险因素的影响：一项为期1年的开放标签前瞻性研究。
Curr Med Res Opin. 2014 Jun;30(6):997-1005. doi: 10.1185/03007995.2014.898139. Epub 2014 Mar 17.
4
Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome.精神分裂症患者抗精神病药物所致代谢综合征中的代谢激素
J Pers Med. 2022 Oct 5;12(10):1655. doi: 10.3390/jpm12101655.
5
Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia.抗精神病药相关体重增加的策略在精神分裂症患者中的应用。
Expert Opin Drug Saf. 2019 Dec;18(12):1149-1160. doi: 10.1080/14740338.2019.1674809. Epub 2019 Oct 11.
6
[Schizophrenia, diabetes mellitus and antipsychotics].[精神分裂症、糖尿病与抗精神病药物]
Encephale. 2004 Jul-Aug;30(4):382-91. doi: 10.1016/s0013-7006(04)95452-8.
7
Metabolic complications of schizophrenia and antipsychotic medications--an updated review.精神分裂症及抗精神病药物的代谢并发症——最新综述
East Asian Arch Psychiatry. 2013 Mar;23(1):21-8.
8
Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome.伴有或不伴有代谢综合征的精神分裂症患者使用非典型抗精神病药物治疗后体脂及相关生化参数的变化
Front Psychiatry. 2019 Nov 1;10:803. doi: 10.3389/fpsyt.2019.00803. eCollection 2019.
9
Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia.第二代抗精神病药物引起的线粒体改变：对精神分裂症患者代谢综合征风险增加的影响。
Eur Neuropsychopharmacol. 2018 Mar;28(3):369-380. doi: 10.1016/j.euroneuro.2018.01.004. Epub 2018 Feb 12.
10
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.体重增加后换用阿立哌唑进行抗精神病治疗的代谢影响：一项试点研究。
J Clin Psychopharmacol. 2007 Aug;27(4):365-8. doi: 10.1097/JCP.0b013e3180a9076c.
引用本文的文献
1
Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review.精神分裂症患者口服突触后抗多巴胺能抗精神病药物之间转换的策略：一项系统综述
CNS Drugs. 2025 Jul 23. doi: 10.1007/s40263-025-01206-3.
2
Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).精神分裂症患者的代谢综合征：潜在机制与治疗方法（综述）
Mol Med Rep. 2025 May;31(5). doi: 10.3892/mmr.2025.13479. Epub 2025 Feb 28.
3
Association of antipsychotic drugs on type 2 diabetes mellitus risk in patients with schizophrenia: a population-based cohort and in vitro glucose homeostasis-related gene expression study.抗精神病药物与精神分裂症患者 2 型糖尿病风险的相关性：一项基于人群的队列研究和体外葡萄糖稳态相关基因表达研究。
BMC Psychiatry. 2024 Oct 30;24(1):751. doi: 10.1186/s12888-024-06222-z.
4
Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and hepatic lipid homeostasis gene expression.抗精神病药物对精神分裂症患者高脂血症风险的影响：基于人群的队列研究及肝脏脂质稳态基因表达的证据
Front Med (Lausanne). 2023 Jun 22;10:1137977. doi: 10.3389/fmed.2023.1137977. eCollection 2023.
5
Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second‑generation antipsychotics (Review).钠-葡萄糖协同转运蛋白2抑制剂对接受第二代抗精神病药物治疗的精神障碍患者代谢状态的影响（综述）
Exp Ther Med. 2023 Feb 6;25(3):125. doi: 10.3892/etm.2023.11824. eCollection 2023 Mar.
6
Influencing factors of obesity in community patients with deficit schizophrenia: a cross-sectional study.社区缺陷型精神分裂症患者肥胖的影响因素：一项横断面研究。
Eur J Med Res. 2022 Jun 11;27(1):90. doi: 10.1186/s40001-022-00706-y.
本文引用的文献
1
Add-on pharmacotherapy for patients with first-episode schizophrenia: a clinical perspective.首发精神分裂症患者的附加药物治疗：临床视角
Eur J Clin Pharmacol. 2021 Jun;77(6):931-932. doi: 10.1007/s00228-020-02973-2. Epub 2020 Jul 29.
2
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.在利培酮治疗 12 个月后换用鲁拉西酮：一项 6 个月开放性研究的结果。
BMC Psychiatry. 2020 May 5;20(1):199. doi: 10.1186/s12888-020-02523-1.
3
Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication).一项事后分析，在一项长期研究（二次发表）中，调查布瑞哌唑在从其他抗精神病药物转换过来的日本精神分裂症患者中的安全性和有效性。
Neuropsychopharmacol Rep. 2020 Jun;40(2):122-129. doi: 10.1002/npr2.12107. Epub 2020 Apr 15.
4
Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial.二甲双胍附加治疗与抗精神病药物换药 vs. 持续抗精神病药物治疗加健康生活方式教育用于患有严重精神疾病的超重或肥胖青少年：IMPACT试验结果
World Psychiatry. 2020 Feb;19(1):69-80. doi: 10.1002/wps.20714.
5
Stopping and switching antipsychotic drugs.停用和更换抗精神病药物。
Aust Prescr. 2019 Oct;42(5):152-157. doi: 10.18773/austprescr.2019.052. Epub 2019 Oct 1.
6
Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia.抗精神病药相关体重增加的策略在精神分裂症患者中的应用。
Expert Opin Drug Saf. 2019 Dec;18(12):1149-1160. doi: 10.1080/14740338.2019.1674809. Epub 2019 Oct 11.
7
Lifestyle Interventions for Weight Management in People with Serious Mental Illness: A Systematic Review with Meta-Analysis, Trial Sequential Analysis, and Meta-Regression Analysis Exploring the Mediators and Moderators of Treatment Effects.严重精神疾病患者体重管理的生活方式干预：一项系统评价，包括荟萃分析、试验序贯分析和荟萃回归分析，以探索治疗效果的中介因素和调节因素
Psychother Psychosom. 2019;88(6):350-362. doi: 10.1159/000502293. Epub 2019 Sep 13.
8
The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials.饮食改善对抑郁和焦虑症状的影响：随机对照试验的荟萃分析。
Psychosom Med. 2019 Apr;81(3):265-280. doi: 10.1097/PSY.0000000000000673.
9
Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study.成功将急性精神分裂症患者从其他抗精神病药物切换为布瑞哌唑：一项随机、双盲、维持治疗研究的事后分析中比较临床医生对交叉滴定方案的选择。
CNS Spectr. 2019 Oct;24(5):507-517. doi: 10.1017/S1092852918001086.
10
Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort.代谢综合征和疾病严重程度可预测精神分裂症患者 1 年随访时的复发：FACE-SZ 队列研究。
J Clin Psychiatry. 2018 Sep 18;79(6):17m12007. doi: 10.4088/JCP.17m12007.
Zotero 插件